Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
This research study is investigating a new medicine called Tuvusertib for individuals living with advanced solid tumours. The main goal is to understand how Tuvusertib moves through the body, how it's processed, and how it leaves the body. Specifically, researchers want to compare how much of the medicine gets into the bloodstream when taken by mouth versus other methods. This is a very early-stage study, often called a Phase 1 study, which helps scientists learn about the medicine's basic actions and safety before it's tested in larger groups of people. It’s part of a bigger effort to find new treatment options for cancer.
At a glance
What is this study about?
This study is about a new medicine called Tuvusertib, which is being explored as a potential treatment for advanced solid tumours – these are cancers that have grown from a solid mass and may have spread. The medical term for this study is a 'Human Mass Balance and Absolute Bioavailability Study', which sounds complicated, but it simply means researchers want to follow the medicine's journey inside the body.
Imagine you take a medicine; this study helps scientists understand where it goes, how quickly it works, how it's changed by the body, and how the body eventually gets rid of it. They also want to compare how much of the medicine actually gets into your bloodstream when you take it by mouth versus if it were given in a different way. This information is really important because it helps doctors figure out the best way to give the medicine and the right dose for patients.
Studies like this are a crucial first step in developing new medicines. By understanding these basic processes, scientists can make sure the medicine is being used as effectively as possible and help ensure its safety for future patients. This kind of research helps pave the way for potential new treatments for serious illnesses.
Key takeaways
- This study is testing a new medicine, Tuvusertib, for advanced solid tumours.
- It's an early-stage (Phase 1) study focused on understanding how the body handles the medicine.
- The study is open to adults aged 18 and over, both men and women.
- Participation involves taking the medicine and having tests like blood samples.
- You won't necessarily get better, but you'll help understand the medicine for future patients.
- You can stop participating at any time.
Who may be eligible?
To be able to join this study, participants must be at least 18 years old. There's no upper age limit, meaning older adults can also take part. This study is open to both men and women.
The main requirement for joining is having advanced solid tumours. This means your cancer started as a solid growth in an organ and has progressed. Specific details about your type of cancer and your overall health will be checked by the study team to make sure it's safe and appropriate for you to participate.
It's important to remember that joining a clinical study has certain health requirements. The study team will review your medical history and conduct tests to see if you meet all the criteria. This is to ensure your safety and that the study results are clear and reliable.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of advanced solid tumours?
- Are you able to attend study visits and follow medical instructions?
- Are you willing to have regular blood tests and other medical checks?
- Are you comfortable with taking a new, experimental medicine?
What does participation involve?
If you decide to join this study, you might have several visits to the study clinic. During these visits, you'll receive the study medicine, Tuvusertib, and the study team will closely monitor your health. You'll likely have blood tests taken at different times to see how the medicine is moving through your body, and you might also have other tests like urine samples or physical exams.
The study involves taking the medicine and being observed for a period. The exact number of visits, tests, and the total length of your participation will depend on the study plan, but it's designed to gather all the necessary information about how the medicine works in your body. There will also be follow-up appointments after you've finished taking the medicine to ensure you are well.
Potential risks and benefits
Locations (1)
- —UnverifiedHungary
Common questions
What is a 'solid tumour'?
A solid tumour is a mass of abnormal cells that doesn't contain cysts or liquid areas. Most cancers are solid tumours, like those found in the breast, lung, or bowel.
What does 'advanced' mean in this study?
In this study, 'advanced' usually means the cancer has grown or spread beyond its original location, or it hasn't responded to previous treatments.
What is 'Phase 1' of a study?
Phase 1 is the earliest stage of human testing for a new medicine. It mainly focuses on seeing how the medicine affects the body, how it's handled, and checking for safety, rather than treating the disease directly.
Will I definitely get better by joining this study?
No, there's no guarantee that participating in this early-stage study will make you better. The main goal is to understand how the medicine works in the body, which helps future research.
How long will I be in the study if I join?
The exact length of time you'd be in the study will depend on the detailed plan, including how long you take the medicine and how many follow-up visits are needed. The study team can give you specific details.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.